eXoZymes, Inc.
Moat Score — eXoZymes, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | eXoZymes holds a worldwide exclusive UCLA license covering its cofactor-recycling technology and cannabinoid biosynthesis enzymes, giving it real IP protection in its core cell-free platform, though it has not yet proven this translates into a commercially scaled, defensible product. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue, pilot-scale biomanufacturing company, eXoZymes has no demonstrated cost advantage versus cell-based SynBio or petrochemical incumbents; its cost thesis (cheaper feedstock conversion) remains unproven at commercial scale. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no commercial product sales, eXoZymes has no current pricing power; any future pricing power depends on proving its cell-free conversion process is cost-competitive against cell-based and petrochemical alternatives. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in enzymatic biomanufacturing -- one customer's or partner's use of the platform does not make it more valuable to the next. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Grant funders and early research partners (DOE, NIH, Gates Foundation, Shell) have invested time and relationship capital in eXoZymes's specific platform, creating mild switching costs, but there are no locked-in commercial customers yet. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The cell-free enzyme biomanufacturing niche already includes multiple funded competitors (Debut Biotech, Solugen, Codexis, Enzymit, and others), several larger and better resourced, so the market is not naturally limited to just one or two efficiently-scaled players. |